INTRODUCTION
Extremely-low-birth-weight (ELBW) infants are at high risk of mortality and acute life-threatening events, such as pneumothorax.
Review of the Vermont Oxford Network (VON) Database for the 1998-1999 period demonstrates an overall mortality of approximately 26% for all infants <1000 g birth weight and an incidence of pneumothorax of approximately 11% in this population. The majority of these ELBW infants are <28 weeks' gestation, require intubation (90%), and receive artificial surfactant (85%) at some point during their hospitalization. 1, 2 The use of antenatal steroids in high-risk pregnancies and the administration of postnatal surfactant have significantly improved the morbidity and mortality rates of ELBW infants over the past decade. Nevertheless, there remain significant interinstitutional variations in VON outcomes such as mortality (26%, with an interquartile range of 15% to 33%) and pneumothorax (11%, interquartile range of 0% to 16%). 2 These interinstitutional variations in outcomes suggest that knowledge gaps may exist between the awareness of best practice clinical methods and actual clinical practice. 3 -8 Clinical process improvement methods have the potential to significantly reduce the incidence of adverse events seen in hospitals and other clinical settings and to decrease the variability that exists in outcomes between institutions. 3 -9 Horbar et al. 8 demonstrated that adoption of neonatal ''best practices,'' using a multidisciplinary clinical process improvement model, could result in significant reductions in nosocomial infection in a multi-institutional trial. Many other clinical investigations using clinical process improvement models have found similar favorable improvements in clinical outcomes in a number of other pediatric and adult health care areas. 5 -7,9 Despite these examples, many health care professionals remain unconvinced about the methods involved in quality improvement models in health care settings. Physicians are trained to think independently and they have difficulty embracing multidisciplinary systems-improvement efforts involving other health care professionals. 7 Acquisition and transmission of knowledge is also labor intensive and difficult to perform so that, without clear clinical benefits and/or the opportunity to efficiently reduce costs, many institutions are unwilling to invest the resources necessary to participate in collaborative quality improvement trials. 4 -7 In this report, we describe the positive benefits of using evidencebased medical resources and a multidisciplinary clinical process improvement approach to reduce the incidence of pneumothorax in infants <28 weeks' gestational age.
OBJECTIVE:
To develop multidisciplinary clinical process improvement methods using evidence -based medicine to decrease the incidence of pneumothorax in a NICU.
STUDY DESIGN:
All inborn infants < 28 weeks' gestation ( n = 79 ) served as the historical baseline group. A prospective protocol, using evidence -based medicine and a rapid -cycle, multidisciplinary clinical process improvement method, was designed to measure changes in the incidence of pneumothorax in subsequent infants of similar gestational ages.
RESULTS:
Sixty consecutive inborn infants < 28 weeks' gestational age comprised the study group. In comparison to the historical control group, there was a significant reduction in the incidence of pneumothorax ( from 26.6% to 10%, p = 0.018 ) and in mortality ( 36.7% to 15%, p = 0.007 ) without adversely affecting any other measured outcome variable.
CONCLUSIONS:
Introduction of multidisciplinary clinical process improvement methods can significantly decrease the incidence of adverse outcomes in neonatal intensive care units. 
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METHODS

Study Population
This study was prospectively designed using a retrospective, historical comparison group. The Institutional Review Board at our institution approved this study and waived the parental consent requirement secondary to the nature of the study design. The historical comparison group included all inborn infants identified in our VON database who were <28 weeks' gestational age and who were admitted to the neonatal intensive care unit (NICU) of the Greenville Hospital System from January 1998 to December 1999 (n=79). Epidemiological data obtained included birth weight, gestational age, sex, race, delivery mode, size appropriate for gestational age, exposure to antenatal steroids, exposure to surfactant, and exposure to high-frequency oscillating ventilation (HFOV). The primary outcome variable was the presence of pneumothorax (defined as extrapleural air). Other secondary variables included the age (days) of pneumothorax occurrence, presence of severe intraventricular hemorrhage, overall mortality, length of hospital stay for surviving infants, and mortality in patients with a pneumothorax. The study group included 60 consecutive inborn patients <28 weeks' gestational age using obstetrical dating admitted to the NICU of the Greenville Hospital System from January 2000 through May 2001 (n=60). The sample size was calculated based on the hypothesis that the institution of a uniform policy for NICU management of this population of infants would reduce the incidence of pneumothorax from that of historical controls by 50% (alpha error of 0.05 and beta error of 0.80).
Evidence-Based Medicine Review
In the last quarter of 1999, the neonatal physicians (n=5) reviewed the published literature regarding reduction of pneumothoraces in preterm infants. Meta-analysis reviews of surfactant administration demonstrated decreased rates of pneumothoraces and mortality in premature infants with respiratory distress syndrome. 10, 11 Natural surfactant extracts were superior to synthetic surfactant extracts and ''prophylactic'' administration of surfactant in infants <30 weeks' gestational age was superior to ''rescue'' surfactant in this same population of patients. 10, 11 The summary conclusion of the surfactant studies stated that for every 100 infants <30 weeks' gestation treated with surfactant prophylactically, there would be two fewer pneumothorax events and five fewer deaths. 10, 11 Based on the conclusions of these reviews, a uniform policy was proposed to electively intubate all infants <28 weeks' gestational age in the delivery room and administer a natural surfactant extract. We selected Infasurf 1 , a calf lung lavage surfactant, as the natural surfactant in our study population. In contrast, our historical control population had been treated with a natural bovine lung-mince surfactant, Survanta 1 , which was in common use before the U. commercially available natural surfactants demonstrate no longterm differences in clinical outcomes.
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Clinical Process Improvement Modeling A multidisciplinary team was created containing members of the nursing staff, respiratory therapy staff, neonatal nurse practitioners, and neonatal physicians. The policy of delivery room administration of prophylactic surfactant administration was discussed and over the course of several meetings, a rapid cycle for learning and improvement was instituted as outlined by Plsek 5 and others. 3 -9 The specific aim of our group was to reduce the incidence of pneumothorax by 50% in the <28 weeks' gestational age infant population. We created a one-page data-tracking sheet for each study patient that was completed by the respiratory therapy team at 7 days of chronological age. Additional data endpoints were abstracted and updated from our patient database and a summary graphic of these outcome variables for all study patients was generated monthly and displayed in a poster format in our NICU.
During the study time period, we incorporated several other respiratory clinical plans of care for the study group of infants <28 weeks' gestation at birth (Figure 1) . On admission, all infants were ventilated using pressure-regulated ventilator settings (SIMV or pressure control modes) with a Servo 300 ventilator (SiemensElema, Solna, Sweden). Infants were weaned off the ventilator or placed on high-frequency oscillation at the attending physician's discretion.
Statistical Methods
The prospectively planned primary analysis involved comparing outcomes after enrollment of 60 consecutive inborn infants <28 weeks' gestational age (the study group), with those occurring in 1998-1999 (the control group). These analyses included comparisons of epidemiological and outcome data between groups. The primary outcome variable was the incidence of pneumothorax (defined as any infant with one or more pneumothoraces divided by total infants enrolled in the study). Secondary outcome variables included overall mortality, presence of severe IVH (Papile's classification Grade III to IV), mortality with pneumothorax, age (in days) of pneumothorax occurrence, and length of hospital stay in surviving infants. Continuous variables were compared using the Student's t-test and categorical variables were compared using Fisher's exact test. The relative risk for each primary and secondary outcome variable was initially estimated and multiple logistic regression modeling was employed to adjust these relative risks by selected covariates (estimated gestational age, birth weight, race, gender, and surfactant use). In all cases, the adjusted values were similar or better than the measure values. We have reported the unadjusted values.
RESULTS
Epidemiological Comparisons
The 79 control group patients and 60 study group patients were similar in terms of birth weight, gestational age, percentage of male infants, race, percentage of small for gestational age infants, delivery mode, and antenatal exposure to steroids. Neonates in the study group more often received surfactant than the control group (Table 1) .
Pneumothorax Occurrence and Other Secondary Outcome Variable Occurrence
There was a significant decrease in the incidence of pneumothorax and mortality in the study group when compared to the control group (Table 2 ). Figure 2 graphically demonstrates the decrease in the frequency of pneumothorax events that occurred following the introduction of the clinical process improvement protocol. No infant in either group had more than a single pneumothorax episode. There were four cases of pulmonary interstitial emphysema (PIE) in our control group and two cases in our study group. In our multivariate logistic regression analysis, group assignment (study period vs baseline period) remained an important factor associated with the improvement in each of these outcomes that was independent of estimated gestational age, birth weight, race, gender, delivery mode, antenatal exposure to steroids and surfactant use. There was also a significant difference in age at pneumothorax identification (3±4 days vs 10±2 days, p<0.001) when comparing study and control groups, respectively, and there was a trend toward less death in association with having a pneumothorax ( p=0.077). There were no significant differences in the incidence of severe IVH, the use of highfrequency oscillation support, or hospital length of stay in surviving infants (Table 2) in either univariate or multivariate analysis.
During the study period, all but two study patients received surfactant in the delivery room. These two patients were intubated and surfactant was administered within 1 hour after admission to the NICU. Only one study patient required resuscitation (chest compressions) before surfactant administration. Delivery room surfactant administration appeared safe as there was no acute deterioration in patient condition noted and all endotracheal tubes were in the correct position on NICU admission chest radiographs.
DISCUSSION
We have observed significant decreases in two important outcome variables, pneumothorax, and mortality, in a group of high-risk preterm infants in a single institution using a rapid cycle, evidencebased medicine, clinical process improvement model.
Our study does not allow us to promote a specific clinical practice; however, there were important observations obtained from chart review of our historical control group. Most impressive was the fact that our baseline rate of pneumothorax and mortality was high when compared to the VON. Although our NICU had experience using the Servo 300 ventilator since 1996, the five clinical neonatologists used different surfactant administration strategies (i.e., giving prophylactic surfactant in the delivery room versus waiting for significant signs of respiratory deterioration before intubation and administration of artificial surfactant) and different initial NICU admission ventilator strategies (i.e., differing I-times, ventilator modes, and peak inspiratory pressures) for this population Walker et al.
Reducing the Occurrence of Pneumothorax of patients. We noted that the majority of pneumothoraces in the control group (76%) occurred in the first 72 hours of life with many of these patients (37%) dying in the subsequent 24 to 72 hours. The cumulative arterial PCO 2 values in these patients before the pneumothorax, or during the first 72 hours of life (whichever came first), were <40 mm Hg a significant percentage of the time (52%±23%, data not shown). Thus, we hypothesized that changing individualized clinical management strategies to a more uniform strategy of care during the first week of life could decrease the incidence of pneumothorax in our high-risk population of patients by decreasing delays in surfactant administration and avoiding excessive periods of overventilation. Although we have no satisfactory explanation as to why our study group had pneumothoraces at a later postnatal age, these infants typically were on low, stable ventilator settings and their pneumothoraces were much less clinically life threatening than those in the control group. It is possible that we could have reduced our pneumothorax incidence further by more aggressively weaning these patients to nasal CPAP or nasal cannula oxygen. Nevertheless, it is reassuring to note that in the 12 months since the conclusion of our study, we have seen further decreases in the incidence of pneumothorax in this population of infants (7.1%, data not shown). The mortality rate has remained similar to our study population. Our findings demonstrate that prospectively planned, evidencebased changes in care can improve targeted outcomes. Our results are not altered by multivariate logistic analysis suggesting that they are not explained by chance or by changes in the demographics of the patients for whom we provided care. Review of the annual reports from an internationally recognized benchmark shows no timerelated changes in these outcomes between 1995 and 2000, so we do not believe that the risk for these outcomes are related to universal improvements in neonatal care. 1,2,13 -16 We recognize that there are limitations to any retrospective, study designs. Sample sizes may be inadequate to reflect larger populations and nonrandomized study groups may result in bias. Subtle, but differing, management approaches between any of the NICU disciplines during the two time periods may also have gone unrecognized. We attempted to control for the former limitations by comparing relevant epidemiological covariables between our control and study groups. Although there were no notable differences (with the exception of surfactant exposure), we may not have included all of the relevant covariables. Two other limitations of unblinded quality improvement projects are the so-called ''Hawthorne effect,'' in which outcomes improve once workers know they are being observed, and the ''regression to the mean'' phenomenon that occurs whenever adverse events that occur in relatively large frequency (i.e., the high pneumothorax and mortality rates in our <28 weeks' gestational age historical control group) are identified and intervened upon. 17 
CONCLUSION
The findings in this study demonstrate that the incidence of pneumothorax and mortality could be significantly reduced in a high-risk population of ELBW infants by adopting multidisciplinary, rapid-cycle, clinical process improvement programs and utilizing available evidence-based medicine. We speculate that combining clinical process improvement methods with evidence-based medicine and/or ''best practice'' protocols will result in improvements in outcomes associated with patient morbidity and mortality, improvements in cost-efficient practice, and reductions in interinstitutional variations in clinical outcomes.
